Home
Law & policy

Law & policy

European Commission to propose radical new SEP/FRAND regime with major consequences for patent owners

Draft EU rules are set to empower EUIPO with mandatory essentiality checking framework but kickback expected

How the UPC will likely affect invalidation proceedings in Turkey

While Turkey is not a UPC member state, the UPC’s lack of case law means that it will rely on EPO jurisprudence – a crucial element of Turkish judicial proceedings. It is thus highly likely that UPC proceedings and EPO evaluations will have a big impact on one another.

Enlarged Board of Appeal fails to offer clear guidance in highly-anticipated “plausibility” opinion

The EBA has not laid out clear rules about when post-filed evidence can be used to demonstrate technical effect

Latest content

Regional courts unmoved by new disproportionality amendment to the German Patent Act

In what can be seen as a relief for patent holders, the new disproportionality exception for the enforcement of patent injunctions has left the German district courts' strict approach to injunctions unchanged.

08 March 2023

Why urgency is critical for injunctive relief in Greece

Under the Greek Patent Law, European patent applicants can enjoy provisional protection against potential infringers, so long as they successfully carry out certain formalities and can justify that their request is sufficiently urgent.

08 March 2023

US commenters warn of ‘unintended consequences’ in pharma patent crackdown

Potential initiatives to limit continuation practice are causing deep divides in the life sciences patent community – causing technology licensors and Big Tech to take sides

07 March 2023

Square peg in a round hole: the dangers of expanding the TRIPS waiver

Saturday Opinion: Disseminating covid diagnostics and therapeutics is critical, but attempting to do so via the TRIPS waiver extension is rife with unintended consequences

04 March 2023

UK Supreme Court becomes highest court to consider DABUS/AI inventorship dispute

The country’s highest court grappled with questions that are fundamental to the future of patent law

03 March 2023

Public criticisms of pharma patents are “way overstated”, Kathi Vidal tells IAM

The USPTO director shares her thoughts on life sciences IP rights and ongoing collaboration with the FDA

02 March 2023

A comeback for injunctions would help to revive US patent leadership

Without significant reforms that restore the right to exclude, lower costs and clarify eligibility, SMEs will remain second class citizens and the big calls on FRAND and SEPs will be made in Europe

02 March 2023